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Fibrinogen Containing γ′ Chains; Is the Assay
Measuring What Farrell's Group Expects?
Kevin R. Siebenlist

Department of Biomedical Sciences, College of Health Sciences, Marquette University, Milwaukee, WI
Dr Farrell has objected to certain findings in our paper1 that do not agree with his published work2: for example,
in our hands, factor XIII (fXIII) activation in the presence of fibrinogen 2 (γA-γ′) was slower than with fibrinogen 1
(γA-γA). To explain the differences, we suggested that the fibrinogen 2 used in his experiments was likely to have
contained fXIII that had coeluted with the fibrinogen 2.As far as we can determine, Farrell's group did not
process the fibrinogen 2 in a manner that would have removed the fXIII present in chromatographically isolated
fibrinogen 2.3 Contrary to Dr Farrell's assertion, we very carefully redescribed our method for rendering
fibrinogen 2 fXIII free and how the product was analyzed and shown to be fXIII free.1,3
Farrell asserted that his “activity” assay for fXIII activation was more appropriate than activation peptide
cleavage from fXIII. Activation peptide release is an accepted and often-used surrogate for measuring fXIII
activation. Furthermore, activation peptide release is the rate limiting step of fXIII activation, not the Ca++mediated dissociation of A* from the B subunits.

To support the contention that the fibrinogen 2 Farrell's group used was depleted of fXIII, he included some
unpublished experiments in his letter. The methodological design of these experiments raises more questions
than they answer. First, since chromatographic separation of fibrinogen 1 from fibrinogen 2 results in fXIII-free
fibrinogen 1, why was transglutaminase activity observed with fibrinogen 1 alone? Second, we previously
demonstrated that “unactivated” fXIII, such as is present in chromatographically purified fibrinogen 2 and in the
activation mixtures that Farrell measured in his assay, cross-links fibrin almost as rapidly as thrombinactivated factor XIIIa. Factor XIII also cross-links fibrinogen and artificial substrates, but at slower rates.4 Since
only one (ie, biotinylated pentylamine incorporation into dimethylcasein) of several reactions (eg, fibrin(ogen)
cross-linking, dimethylamine incorporation into fibrin(ogen), biotinylated pentylamine incorporation into
fibrin(ogen)) was measured in his assay, we wonder what the effect of competing fXIII substrate(s), namely
fibrin(ogen), was on the pentylamine incorporation into dimethylcasein?
Dr Farrell also posited that the discrepancies in FPA release between our paper and one by Cooper et al5 might
be explained by contaminants or variable degrees of fibrinogen degradation in our preparations. Our
explanation is simpler. Differences between our results and those of Cooper et al5 were due to the lower levels
of thrombin we employed, and those lower concentrations enabled us to measure differences in FPA release
between fibrinogen 2 and fibrinogen 1. Other experiments in our paper, showing down-regulation of thrombin
catalytic activity (kcat) when bound to fibrin 2 γ′ chains, provide more than adequate support for our explanation
and also for the slower release of activation peptide from fXIII in the presence of fibrinogen 2.
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